CYTOKINETICS, INCORPORATED Deferred Tax Assets, Deferred Income
CYTOKINETICS, INCORPORATED (CYTK) had Deferred Tax Assets, Deferred Income of $0 as of 2022-12-31, per its 10-K filed 2023-03-01.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2023-03-01
- 2022-12-31: Deferred Tax Assets, Deferred Income $0.00.
- 2021-12-31: Deferred Tax Assets, Deferred Income $18.61M.
- 2020-12-31: Deferred Tax Assets, Deferred Income $0.00.
| Period end | Deferred Tax Assets, Deferred Income |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-01 |
| 2021-12-31 | $18.61M 10-K · filed 2023-03-01 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |